265 related articles for article (PubMed ID: 18682296)
1. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.
Vainchenker W; Dusa A; Constantinescu SN
Semin Cell Dev Biol; 2008 Aug; 19(4):385-93. PubMed ID: 18682296
[TBL] [Abstract][Full Text] [Related]
2. Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.
Constantinescu SN; Leroy E; Gryshkova V; Pecquet C; Dusa A
Biochem Soc Trans; 2013 Aug; 41(4):1048-54. PubMed ID: 23863177
[TBL] [Abstract][Full Text] [Related]
3. Lymphoid malignancies: Another face to the Janus kinases.
Scott LM
Blood Rev; 2013 Mar; 27(2):63-70. PubMed ID: 23340138
[TBL] [Abstract][Full Text] [Related]
4. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains.
Williams NK; Bamert RS; Patel O; Wang C; Walden PM; Wilks AF; Fantino E; Rossjohn J; Lucet IS
J Mol Biol; 2009 Mar; 387(1):219-32. PubMed ID: 19361440
[TBL] [Abstract][Full Text] [Related]
5. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
6. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
7. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
8. Janus kinases in immune cell signaling.
Ghoreschi K; Laurence A; O'Shea JJ
Immunol Rev; 2009 Mar; 228(1):273-87. PubMed ID: 19290934
[TBL] [Abstract][Full Text] [Related]
9. JAK: Not Just Another Kinase.
Agashe RP; Lippman SM; Kurzrock R
Mol Cancer Ther; 2022 Dec; 21(12):1757-1764. PubMed ID: 36252553
[TBL] [Abstract][Full Text] [Related]
10. The use of structural biology in Janus kinase targeted drug discovery.
Alicea-Velázquez NL; Boggon TJ
Curr Drug Targets; 2011 Apr; 12(4):546-55. PubMed ID: 21126226
[TBL] [Abstract][Full Text] [Related]
11. The Janus kinases (Jaks).
Yamaoka K; Saharinen P; Pesu M; Holt VE; Silvennoinen O; O'Shea JJ
Genome Biol; 2004; 5(12):253. PubMed ID: 15575979
[TBL] [Abstract][Full Text] [Related]
12. Mining for JAK-STAT mutations in cancer.
Constantinescu SN; Girardot M; Pecquet C
Trends Biochem Sci; 2008 Mar; 33(3):122-31. PubMed ID: 18291658
[TBL] [Abstract][Full Text] [Related]
13. The molecular regulation of Janus kinase (JAK) activation.
Babon JJ; Lucet IS; Murphy JM; Nicola NA; Varghese LN
Biochem J; 2014 Aug; 462(1):1-13. PubMed ID: 25057888
[TBL] [Abstract][Full Text] [Related]
14. The JAK kinases: not just another kinase drug discovery target.
Wilks AF
Semin Cell Dev Biol; 2008 Aug; 19(4):319-28. PubMed ID: 18721891
[TBL] [Abstract][Full Text] [Related]
15. The two faces of myeloproliferative neoplasms: Molecular events underlying lymphoid transformation.
Holroyd A; Cross NC; Macdonald DH
Leuk Res; 2011 Oct; 35(10):1279-85. PubMed ID: 21722956
[TBL] [Abstract][Full Text] [Related]
16. JAK2 the future: therapeutic strategies for JAK-dependent malignancies.
LaFave LM; Levine RL
Trends Pharmacol Sci; 2012 Nov; 33(11):574-82. PubMed ID: 22995223
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
18. Janus Kinases in Leukemia.
Raivola J; Haikarainen T; Abraham BG; Silvennoinen O
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33672930
[TBL] [Abstract][Full Text] [Related]
19. JAK mutations in high-risk childhood acute lymphoblastic leukemia.
Mullighan CG; Zhang J; Harvey RC; Collins-Underwood JR; Schulman BA; Phillips LA; Tasian SK; Loh ML; Su X; Liu W; Devidas M; Atlas SR; Chen IM; Clifford RJ; Gerhard DS; Carroll WL; Reaman GH; Smith M; Downing JR; Hunger SP; Willman CL
Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9414-8. PubMed ID: 19470474
[TBL] [Abstract][Full Text] [Related]
20. Regulation of T cell homeostasis by JAKs and STATs.
Ross JA; Nagy ZS; Cheng H; Stepkowski SM; Kirken RA
Arch Immunol Ther Exp (Warsz); 2007; 55(4):231-45. PubMed ID: 17659375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
